{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-26-000077","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2026-09-09T12:33:41+00:00","discovered_at":"2026-09-09T12:35:00.391295+00:00","generated_at":"2026-09-09T12:35:08.075216+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris details XP-8121 Phase 3 plan; expects $1-3B peak revenue, launch in 2030","bullets":["Phase 3 Cornerstone study: 500 patients, 1:1 vs oral levothyroxine, 54 weeks, primary endpoint TSH normal at weeks 48/54.","Topline results expected late 2028; FDA approval and launch anticipated 2030.","Peak net revenue potential $1-3 billion for once-weekly subcutaneous levothyroxine.","Additional studies: pediatric (Capstone), special population (Touchstone), real-world evidence.","KOL Dr. David Robertson to serve as Cornerstone investigator."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-26-000077","json":"https://secwatch.observer/filing/0001867096-26-000077.json","markdown":"https://secwatch.observer/filing/0001867096-26-000077.md","text":"https://secwatch.observer/filing/0001867096-26-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/0001867096-26-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/xers-20260909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T12:35:08.075216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}